My lab aims to understand the mechanisms that underlie numerical and structural chromosome aberrations in cancer at a molecular level, which also involves understanding how normal cells replicate and segregate their genomes.
We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
Our research group focuses on understanding how centrosome amplification impacts tumour progression and how we can target cells with amplified centrosomes to develop new cancer therapies.
My research group works on molecular pathology, genetics and progression of leukaemia and lymphomas, aiming to improve on current diagnostic, prognostic and treatment strategies.
My group aims to discover the epigenetic changes taking place during cancer initiation and develop potential drugs that can prevent these changes which may be abnormal but reversible, before many damaging mutations occur.